Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorKanazawa, Hiroki
dc.contributor.authorSaavedra, Oscar M.
dc.contributor.authorMaianti, Juan Pablo
dc.contributor.authorYoung, Simon A.
dc.contributor.authorIzquierdo, Luis
dc.contributor.authorSmith, Terry K.
dc.contributor.authorHanessian, Stephen
dc.contributor.authorKondo, Jiro
dc.date.accessioned2019-05-14T23:38:01Z
dc.date.available2019-05-14T23:38:01Z
dc.date.issued2018-08-10
dc.identifier.citationKanazawa , H , Saavedra , O M , Maianti , J P , Young , S A , Izquierdo , L , Smith , T K , Hanessian , S & Kondo , J 2018 , ' Structure-based design of a eukaryote-selective antiprotozoal fluorinated aminoglycoside ' , ChemMedChem , vol. 13 , no. 15 , pp. 1541-1548 . https://doi.org/10.1002/cmdc.201800166en
dc.identifier.issn1860-7179
dc.identifier.otherPURE: 255514851
dc.identifier.otherPURE UUID: 872ed9fc-a1d0-4a5a-8c91-ff5437701528
dc.identifier.othercrossref: 10.1002/cmdc.201800166
dc.identifier.otherScopus: 85050614558
dc.identifier.otherWOS: 000441432700006
dc.identifier.otherORCID: /0000-0003-1072-905X/work/47725767
dc.identifier.urihttp://hdl.handle.net/10023/17705
dc.descriptionThis work was supported by Grant‐in‐Aid for Young Scientists (B) (No. 26860025) and Grant‐in‐Aid for Scientific Research (C) (No. 17K08248) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT), and partially supported by the Kurata Grant awarded by the Kurata Memorial Hitachi Science and Technology Foundation, the grant provided by the Ichiro Kanehara Foundation and the Platform for Drug Discovery, Informatics, and Structural Life Science from Japan Agency for Medical Research and Development (AMED). H.K. was supported by the Sasakawa Scientific Research Grant from the Japan Science Society and the SUNBOR Scholarship. We thank the Photon Factory for provision of synchrotron radiation facilities (Photon Factory Proposal No. 2014G532) and acknowledge the staff of the NW‐12A and BL‐17A beamlines. We thank our colleague Vu Linh Ly for preparing the hydroxysisomicin intermediate. The Montreal group thanks NSERC for financial support and a fellowship to J.P.M. from the Québec Research Fund: Nature and Technology. The T.K.S. group thanks the Medical Research Council (MR/M020118/1) for current financial support.en
dc.description.abstractAminoglycosides (AG) are antibiotics that lower the accuracy of protein synthesis by targeting a highly conserved RNA helix of the ribosomal A-site. The discovery of AGs that selectively target the eukaryotic ribosome, but lack activity in prokaryotes, are promising as antiprotozoals for the treatment of neglected tropical diseases, and as therapies to read-through point-mutation genetic diseases. However, a single nucleobase change A1408G in the eukaryotic A-site leads to negligible affinity for most AGs. Herein we report the synthesis of 6-fluorosisomicin, the first 6-fluorinated aminoglycoside, which specifically interacts with the protozoal cytoplasmic rRNA A-site, but not the bacterial A-site, as evidenced by X-ray co-crystal structures. The respective dispositions of 6-fluorosisomicin within the bacterial and protozoal A-sites reveal that the fluorine atom acts only as a hydrogen-bond acceptor to favorably interact with G1408 of the protozoal A-site. Unlike aminoglycosides containing a 6-ammonium group, 6-fluorosisomicin cannot participate in the hydrogen-bonding pattern that characterizes stable pseudo-base-pairs with A1408 of the bacterial A-sites. Based on these structural observations it may be possible to shift the biological activity of aminoglycosides to act preferentially as antiprotozoal agents. These findings expand the repertoire of small molecules targeting the eukaryotic ribosome and demonstrate the usefulness of fluorine as a design element.
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofChemMedChemen
dc.rights© 2018, Wiley-VCH Verlag GmbH & KGaA, Weinheim. This work has been made available online in accordance with the publisher’s policies. This is the author created accepted version manuscript following peer review and as such may differ slightly from the final published version. The final published version of this work is available at https://doi.org/10.1002/cmdc.201800166en
dc.subjectAminoglycosidesen
dc.subjectAntiprotozoal activityen
dc.subjectFluorinationen
dc.subjectStructure-based drug designen
dc.subjectX-ray analysisen
dc.subjectQD Chemistryen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectRS Pharmacy and materia medicaen
dc.subjectDASen
dc.subject.lccQDen
dc.subject.lccRMen
dc.subject.lccRSen
dc.titleStructure-based design of a eukaryote-selective antiprotozoal fluorinated aminoglycosideen
dc.typeJournal articleen
dc.description.versionPostprinten
dc.contributor.institutionUniversity of St Andrews.School of Biologyen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.identifier.doihttps://doi.org/10.1002/cmdc.201800166
dc.description.statusPeer revieweden
dc.date.embargoedUntil2019-05-15


This item appears in the following Collection(s)

Show simple item record